ENTRY       D02173                      Drug
NAME        Galantamine hydrobromide (JAN/USP);
            Razadyne (TN);
            Reminyl (TN)
PRODUCT
  GENERIC   GALANTAMINE (American Health Packaging)
            GALANTAMINE (Aurobindo Pharma Limited)
            GALANTAMINE (Aurobindo Pharma Limited)
            GALANTAMINE (Major Pharmaceuticals)
            GALANTAMINE (Rising Health)
            GALANTAMINE (Slate Run Pharmaceuticals)
            GALANTAMINE (Zydus Lifesciences Limited)
            GALANTAMINE (Zydus Pharmaceuticals USA)
            GALANTAMINE HYDROBROMIDE (Aphena Pharma Solutions - Tennessee)
            GALANTAMINE HYDROBROMIDE (Bryant Ranch Prepack)
            GALANTAMINE HYDROBROMIDE (Bryant Ranch Prepack)
            GALANTAMINE HYDROBROMIDE (Bryant Ranch Prepack)
            GALANTAMINE HYDROBROMIDE (Bryant Ranch Prepack)
            GALANTAMINE HYDROBROMIDE (Bryant Ranch Prepack)
            GALANTAMINE HYDROBROMIDE (Bryant Ranch Prepack)
            GALANTAMINE HYDROBROMIDE (Hikma Pharmaceuticals USA)
            GALANTAMINE HYDROBROMIDE (Sun Pharmaceutical Industries)
FORMULA     C17H21NO3. HBr
EXACT_MASS  367.0783
MOL_WEIGHT  368.2655
CLASS       Neuropsychiatric agent
             DG01595  Cholinesterase inhibitor
              DG01593  Acetylcholinesterase inhibitor
             DG01968  Antidementia agent
            Metabolizing enzyme substrate
             DG01644  CYP2D6 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 1190
            ATC code: N06DA04
            Chemical structure group: DG00985
            Product (DG00985): D02173<JP/US>
EFFICACY    Dementia therapeutic agent, Acetylcholinesterase inhibitor
  DISEASE   Dementia of the Alzheimer's type [DS:H00056]
TARGET      ACHE [HSA:43] [KO:K01049]
  PATHWAY   hsa00564(43)  Glycerophospholipid metabolism
            hsa04725(43)  Cholinergic synapse
METABOLISM  Enzyme: CYP2D6 [HSA:1565], CYP3A4 [HSA:1576]
INTERACTION  
STR_MAP     map07056  Agents for Alzheimer-type dementia
            map07220  Cholinergic and anticholinergic drugs
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N06 PSYCHOANALEPTICS
               N06D ANTI-DEMENTIA DRUGS
                N06DA Anticholinesterases
                 N06DA04 Galantamine
                  D02173  Galantamine hydrobromide (JAN/USP) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antidementia Agents
              Cholinesterase Inhibitors
               Galantamine
                D02173  Galantamine hydrobromide (JAN/USP)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              11  Agents affecting central nervous system
               119  Miscellaneous
                1190  Miscellaneous
                 D02173  Galantamine hydrobromide (JAN/USP)
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01595  Cholinesterase inhibitor
               DG01593  Acetylcholinesterase inhibitor
                DG00985  Galantamine
                 D02173  Galantamine hydrobromide
              DG01968  Antidementia agent
               DG00985  Galantamine
                D02173  Galantamine hydrobromide
             Metabolizing enzyme substrate
              DG01644  CYP2D6 substrate
               DG00985  Galantamine
                D02173  Galantamine hydrobromide
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00985  Galantamine
                 D02173  Galantamine hydrobromide
            Drug classes [BR:br08332]
             Neuropsychiatric agent
              DG01968  Antidementia agent
               D02173  Galantamine hydrobromide
            Target-based classification of drugs [BR:br08310]
             Enzymes
              Hydrolases (EC3)
               Carboxylic-ester hydrolases
                ACHE
                 D02173  Galantamine hydrobromide (JAN/USP) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D02173
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D02173
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D02173
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D02173
            Pharmacogenomic biomarkers [br08341.html]
             Polymorphisms and mutations affecting drug response
              D02173
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01595  Cholinesterase inhibitor
               DG01593  Acetylcholinesterase inhibitor
                DG00985  Galantamine
              DG01968  Antidementia agent
               DG00985  Galantamine
             Metabolizing enzyme substrate
              DG01644  CYP2D6 substrate
               DG00985  Galantamine
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                DG00985  Galantamine
DBLINKS     CAS: 1953-04-4
            PubChem: 7849234
            LigandBox: D02173
            NIKKAJI: J220.074K
ATOM        22
            1   X   Br   26.7123  -22.0590
            2   C8y C    21.3562  -22.9628
            3   C1x C    22.4064  -23.7330
            4   N1y N    23.7367  -23.4529
            5   C1x C    24.2969  -22.1927
            6   C8y C    21.3562  -21.5625
            7   C1x C    23.7367  -21.0024
            8   C1z C    22.4064  -20.5123
            9   C1a C    24.6470  -24.5032
            10  C8x C    20.1659  -23.6630
            11  C8x C    18.9756  -22.9628
            12  C8y C    18.9756  -21.5625
            13  C8y C    20.1659  -20.8623
            14  O2a O    17.7854  -20.9324
            15  O2x O    20.5160  -19.2520
            16  C1y C    21.9163  -19.1820
            17  C1x C    22.5465  -18.0617
            18  C1y C    23.9468  -18.0617
            19  C2x C    24.6470  -19.2520
            20  C2x C    23.9468  -20.5123
            21  O1a O    24.6470  -16.8014
            22  C1a C    16.5992  -21.6765
BOND        24
            1     4   5 1
            2     2   6 2
            3     5   7 1
            4     3   4 1
            5     6   8 1
            6     2   3 1
            7     8   7 1 #Down
            8     4   9 1
            9     2  10 1
            10   10  11 2
            11   11  12 1
            12   12  13 2
            13    6  13 1
            14   12  14 1
            15   13  15 1
            16   15  16 1
            17    8  16 1
            18   16  17 1
            19   17  18 1
            20   18  19 1
            21    8  20 1
            22   20  19 2
            23   18  21 1 #Up
            24   14  22 1
///
